
==== Front
Pediatr Rep
Pediatr Rep
pediatrrep
Pediatric Reports
2036-749X
2036-7503
MDPI

10.3390/pediatric16030066
pediatrrep-16-00066
Article
Association of Methylenetetrahydrofolate Reductase (MTHFR) Polymorphism with Osteosarcoma in a Mexican Population
Enriquez-Maldonado Irma G. Conceptualization 1
https://orcid.org/0000-0003-2748-4327
Montes-Galindo Daniel A. Writing – original draft Writing – review & editing 2
https://orcid.org/0000-0002-7783-026X
Ortiz-Lopez Rocio Methodology 3
Ojeda-Ibarra Jesus Methodology 4
https://orcid.org/0000-0003-1478-9068
Martinez-Fierro Margarita L. Validation 5
https://orcid.org/0000-0002-5988-4168
Rodriguez-Sanchez Iram P. Formal analysis 6
Rojas-Martinez Augusto Formal analysis 3
Zavala-Pompa Angel Investigation 4
https://orcid.org/0000-0002-3525-7821
Sanchez-Ramirez Carmen Alicia Investigation 7
Hernandez-Rangel Alejandra E. Writing – review & editing 7
https://orcid.org/0000-0002-8702-0252
Sanchez-Meza Karmina Data curation 7
https://orcid.org/0000-0002-6307-1696
Garza-Veloz Idalia Supervision 5
Rodriguez-Hernandez Alejandrina Supervision 7
https://orcid.org/0000-0001-9848-862X
Delgado-Enciso Ivan Conceptualization Writing – original draft Writing – review & editing Project administration 178*
Aricò Maurizio Academic Editor
1 State Cancerology Institute of Colima, Health Services of the Mexican Social Security Institute for Welfare (IMSS-BIENESTAR), Colima 28085, Mexico; gabyenriquez75@gmail.com
2 Faculty of Chemical Sciences, University of Colima, Coquimatlán 28400, Mexico
3 Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey 64710, Mexicoaugusto.rojasmtz@tec.mx (A.R.-M.)
4 Department of Pathological Anatomy at Monterrey Specialty Hospital No. 25 (IMSS), Monterrey 64460, Mexico
5 Academic Unit of Human Medicine and Health Sciences, Autonomous University of Zacatecas, Zacatecas 98160, Mexico; margaritamf@uaz.edu.mx (M.L.M.-F.); idaliagv@uaz.edu.mx (I.G.-V.)
6 Molecular and Structural Physiology Laboratory, School of Biological Sciences, Autonomous University of Nuevo Leon, San Nicolás de los Garza 66455, Mexico
7 School of Medicine, University of Colima, Colima 28040, Mexicoarodrig@ucol.mx (A.R.-H.)
8 Robert Stempel College of Public Health and Social Work, Florida International University, Miami, FL 33199, USA
* Correspondence: ivan_delgado_enciso@ucol.mx
09 9 2024
9 2024
16 3 786793
23 7 2024
28 8 2024
05 9 2024
© 2024 by the authors.
2024
https://creativecommons.org/licenses/by/4.0/ Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
The methylenetetrahydrofolate reductase (MTHFR) gene 677C➔T polymorphism is capable of altering folate metabolism and can modify certain neoplasia risk. Reports have suggested that folate can have an influence on bone development and so it is of interest to know if the MTHFR 677C➔T polymorphism is associated with the malignant transformation process of this tissue. The polymorphism was determined in 55 patients with osteosarcoma and in 180 healthy individuals. Compared with C/T+C/C genotypes, a 3.7-fold reduction in osteosarcoma probability is possible with the T/T genotype (OR 0.27, CI 95% 0.07–0.82). Undoubtedly, further studies, utilizing large samples and carried out on different populations, are necessary to confirm these results.

methylenetetrahydrofolate reductase
osteosarcoma
folic acid
Mexico
single-nucleotide polymorphism
This research received no external funding.
==== Body
pmc1. Introduction

Folate, a key mediator in the transfer of one-carbon units essential for methylation and nucleotide biosynthesis, plays a crucial role in DNA stability, synthesis, repair, and methylation. There is robust evidence demonstrating that folate has beneficial effects on health outcomes, including mortality, metabolic conditions, cardiovascular diseases (CVDs), neurocognitive disorders, cancers, and various birth outcomes. This body of evidence supports current guidelines advocating for daily folate supplementation, although its precise role in some diseases remains uncertain or debated. The health benefits of folate are thought to arise from several mechanisms. First, folate acts as a cofactor for methionine synthase, an enzyme that facilitates the conversion of homocysteine, thereby establishing an inverse relationship between folate levels and homocysteine levels. Elevated homocysteine (hyperhomocysteinemia) has been associated with higher risks of adverse pregnancy outcomes, cancers, CVDs, and neurological conditions. Second, variations in the 5,10-methylenetetrahydrofolate reductase (MTHFR) enzyme, which directs folate metabolites towards DNA methylation or synthesis pathways, may influence an individual’s susceptibility to certain conditions [1].

Folate metabolism has been shown to have an influence on bone growth [2]. Iqbal et al. showed that the prolonged administration of the antifolate agent, methotrexate (MTX), can suppress bone growth in young mice and that folate administration produces the opposite effect [3]. MTX administered in high doses is one of the therapeutic components used to fight uncontrolled malignant cell growth in bone tissue [4]. In epidemiological studies, folate has been associated with bone formation [5]. Women with osteoporosis have lower serum folate levels, and bone mineral density (BMD) progressively increases as serum folate levels increase [6]. Although complex molecular mechanisms are involved in the proliferation, differentiation, and apoptosis of bone cells, there is also evidence that folate metabolism could be involved in these processes [7,8]. However, it is not yet known if this metabolism could also have an influence on the malignant transformation of bone tissue. The most common primary bone cancer is osteosarcoma (OS), which is characterized by the proliferation of cells that directly produce osteoid [4]. Osteosarcoma has the potential to manifest in any bone throughout the body, although it typically originates in the metaphysis of long bones. While commonly recognized as a sarcoma affecting children, its occurrence follows a two-phase pattern across age groups, with an initial peak during childhood and adolescence, followed by a secondary peak in individuals aged 65 and older [7].

Folate ingestion has been shown to modify certain neoplasia risk, although the mechanism by which this is achieved is not yet clearly understood [9]. Chronic folate deficiency may cause alterations in DNA synthesis or repair, as well as changes in its methylation [9,10]. This could have a role in oncogene activation and in tumor suppressor gene inactivation [10]. However, folate bioavailability, or that of its metabolites, is not solely determined by ingestion, due to the fact that different enzymes participate in its metabolism. One such conspicuous enzyme is MTHFR. It catalyzes the synthesis of 5-methyltetrahydrofolate, the principal form of circulating folate, a carbon donor for homocysteine to methionine remethylation and a precursor of S-adenosylmethionine [11].

S-adenosylmethionine is the methyl group universal donor for methylation reactions, including that of DNA [12]. In 1995, Frostt et al. found a gene variant (polymorphism) in the 677 position (T instead of C) of the MTHFR gene. Whether in its 677T/T homocygote state or its 677C/T heterozygote state, the enzyme activity of this variant is significantly reduced [13]. Individuals with the 677T/T genotype have demonstrated DNA hypomethylation, which may be one of the molecular events taking place in the early stages of carcinogenesis [14].

The 677T variant has been controversially related to different neoplasias. It has been associated with possible greater risk for breast [15], esophageal [16], and stomach cancer [17,18] while at the same time acting as a protective factor against malignant lymphomas [19] and some types of leukemia [20,21]. It was reported in Turkish and Spanish populations that the 677T variant was not associated with OS development [22,23]. However, the association of the same genetic polymorphism with a given disease can be different, depending on the population studied, due to variations in population backgrounds and environments. The 677T variant is not very frequent in Turkey [22]. In contrast, its frequency is one of the highest in the world in Mexico [24]. It is therefore of interest to analyze whether the genetic alteration that affects folate metabolism could have an influence on the malignant transformation of bone tissue in the Mexican population. The present study was carried out as a case–control study to determine if there was an association between the MTHFR 677 polymorphism and OS in a northeastern Mexican population.

2. Materials and Methods

Paraffin-embedded tumor tissue biopsies were obtained from 60 patients diagnosed with OS in the Pathology Department of the Hospital de Especialidades N° 25 del IMSS, in Monterrey, NL, Mexico. Peripheral blood was collected from 180 clinically healthy volunteers for comparison purposes at hospitals in the same city. OS patients and the control group were unrelated Mexican mestizo subjects from northeastern Mexico. The study was approved by the Committee on Ethics of the University of Colima’s School of Medicine, Mexico, authorized by the Department of Education of the Hospital de Especialidades N° 25 del IMSS NL, Mexico, and carried out in compliance with the Declaration of Helsinki. Participants in the control group (clinically healthy volunteers) signed an informed consent form. The Ethics Committee waived the need for informed consent from the patients in the case group, since samples obtained retrospectively and stored in the Department of Pathological Anatomy were analyzed from them, in addition to their clinical data being obtained from the clinical record. The above does not represent a risk for these subjects, guaranteeing anonymity and the protection of personal data. The above was in accordance with the functions provided to the Ethics Committees by the General Health Law on Health Research in Mexico, being a risk-free investigation [25]. DNA was extracted from the paraffin-embedded tissue [26] and peripheral blood [27], using previously described techniques. MTHFR gene 677 polymorphism determination was carried out by PCR restriction fragment length polymorphism (PCR-RFLP) [12]. Ten percent of samples were analyzed using a different genotyping method, namely, allele specific oligonucleotide hybridization [28], and identical results were obtained.

The association between polymorphism and OS was carried out by means of odds ratio (OR) determination with its confidence interval (CI) and the χ2 test, using the EpiInfo 2000 computerized program [29]. The Hardy–Weinberg equilibrium of the genotypic distribution was calculated using the Online HW computerized program [30]. Statistical significance was considered when p < 0.05.

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

3. Results

Twenty-four of the OS patients were women and thirty-six were men, with a mean age of 18 years (8–67-year range). Age and sex differences between the control and OS groups were not shown. OS histological varieties were osteoblastic (53.3%), condroblastic, fibroblastic, telangiectasic (15% each), and small-cell (1.7%). OS was more frequently localized in the distal third of the femur (31.6%), followed by the proximal third of the tibia (21.6%), proximal third of the humerus (16.6%), inferior maxillary bone (11.6%), pelvis (3.3%), femoral diaphysis (3.3%), paranasal sinuses, clavicle, rib, proximal third of the femur, distal third of the tibia, astragalus, and soft tissues of the scapular-humeral region (1.7% in each of the latter locations).

DNA was extracted from the 60 paraffin-embedded OS biopsies and the MTHFR polymorphism was determined in 55 of them and in 180 controls (there was not a sufficient quantity of DNA obtained in 5 of the OS samples). The C/C, C/T, and T/T polymorphism percentages in the OS group were 32.7, 60, and 7.3%, respectively, and 26.7, 51.1, and 22.2% in the control group. Genotype distribution was in accordance with the Hardy–Weinberg equilibrium in the control group but was out of balance in the OS group (p = 0.048). As shown in Table 1, the 677T/T genotype was significantly less likely to be present in OS patients (7.3%) compared with control subjects (22.2%) (p = 0.02), whereas the presence of a single 677T allele (heterozygote) was not different between groups (60% vs. 51.1%, in cases and controls, respectively; p = 0.89).

4. Discussion

The present work indicates that the MTHFR 677TT genotype was significantly less likely to be present in OS patients (7.3%) compared with control subjects (22.2%) (p = 0.02), in a Mexican population. Various reports have suggested that folate metabolism may have an influence on bone development. Folate ingestion during pregnancy has a positive effect on fetal BMD [31,32]. Folate levels in blood have the same positive BMD effect in post-menopausal women [33,34,35]

On the other hand, a deficiency in folate metabolism, brought on by the administration of anti-folate agent MTX, has been shown to possibly suppress bone growth in mice [3]. On the genetic level, the MTHFR 677T/T genotype has a negative effect on folate metabolism causing reduced MTHFR activity [36]. It catalyzes the synthesis of 5-methyltetrahydrofolate, the principal form of circulating folate, a carbon donor for homocysteine to methionine remethylation and a precursor of S-adenosylmethionine. S-adenosylmethionine is the methyl group universal donor for methylation reactions, including that of DNA [27]. The MTHFR 677T/T genotype has been associated with BMD decrease [37] and fractures due to osteoporosis [38], suggesting that this genotype, as well as folate levels, are capable of having an influence on bone metabolism. MTHFR C677T might have some relationship with liver toxicity and fever after MTX therapy [39]. It has been reported that in pediatric osteosarcoma patients, the MTHFR 667TT polymorphism is associated with a higher relapse rate, although it does not predict overall survival. Therefore, identifying the MTHFR genotype could serve as an important predictor for assessing the likelihood of relapse and may be useful for risk stratification in future treatment protocols. Patients with this genotype may exhibit reduced sensitivity to Methotrexate treatment, suggesting that alternative chemotherapeutic agents could be more effective [40]. However, further studies on this topic would be necessary to implement it as a marker to guide treatment.

The present work indicates that the MTHFR 677T/T genotype probably produces a 3.7-fold OS risk reduction in a Mexican population. The above-mentioned information suggests that TT genotype was significantly less frequent in the OS group. Seen from a different perspective, it could be said that CC genotype was more frequent in OS (Table 1). The probable protection of the TT genotype against OS development could be the result of a negative effect of the mutant genotype on the accelerated and uncontrolled growth of neoplastic bone cells. However, this hypothesis still needs to be proved.

Ozger et al. (2008) and Patiño-Garcia et al. (2009) reported that the MTHFR 677 polymorphism may not be an important factor in OS development in Turkish and Spanish populations [22,23]. Although they found no association between MTHFR genotypes and OS, they observed that the MTHFR 677C allele was more frequent in the OS group. These findings partially align with the results of the present study, suggesting the need for further research to confirm the role of MTHFR 677 polymorphism genotypes in osteosarcoma. The influence of MTHFR 677 polymorphism genotypes varies across different neoplasms, ethnic groups, and methylation patterns, complicating our understanding of its role in carcinogenesis [41,42]. This complexity is further exacerbated by interactions with environmental factors [24], including nutritional influences [43,44].

In the Mexican population, the 677TT genotype has previously been identified as reducing the likelihood of developing cervical cancer, but only in women with other risk factors such as multiple gestations and an early onset of sexual activity [24]. The variability in the influence of MTHFR 677 genotypes across different neoplasms and populations is evident. For example, the T allele is associated with a decreased risk of prostate cancer in the Asian population, but not in other populations [45]. Conversely, this same allele has been linked to an increased risk of bladder cancer [42], a finding that is also observed in ovarian cancer, but only in the Asian population [41]. In breast cancer, the role of the alleles of this polymorphism varies depending on the studied population [46], while in gastric cancer, it has been concluded that the genotypes of this polymorphism are not associated with the disease [47]. In acute lymphoblastic leukemia (ALL), the most common childhood cancer, the CC and CC + CT genotypes have been found to increase the risk of ALL in Asian children, with the TT genotype being significantly less common among ALL patients. However, this relationship was not observed in Caucasians [48]. This important variability between populations and neoplasms may reasonably explain the lack of complete concordance between previous reports analyzing this polymorphism in OS and the present study.

The lower proportion of the 677T/T genotype in patients with OS is congruent with reports that have suggested that MTX and the 677T/T genotype may have a negative influence on bone growth, at least when it is neoplastic. A protective factor of the 677T/T genotype against neoplasia development has been reported for certain types of leukemia [18,20], cancer of the bladder [49,50], and in some reports of colon cancer [51]. However, the mechanism by which this genotype helps protect individuals from neoplasia is not clear. It has been proposed that the reduced activity of the MTHFR enzyme causes a less efficient transformation of 5, 10, methylenetetrahydrofolate to 5 methylenetetrahydrofolate. This causes alterations in the homocysteine cycle but brings with it an intracellular accumulation of folate metabolites that take part in the process of DNA synthesis, which could confer protection [21]. The 677T/T genotype has also been associated with changes in DNA methylation (DNA hypomethylation in general and hypermethylation in some genes) [14], and multiple changes at this level have been detected in OS [23,52]. This suggests that the association between the MTHFR 677 polymorphism and OS could be partly caused by methylation patterns which are favored or limited by the presence of MTHFR genotypes.

A relationship has been found between the 677T/T genotype and methotrexate toxicity in osteosarcoma patients [53,54,55]. Despite the fact that this is a very interesting subject, the association between the MTHFR genotype and the response to chemotherapy or toxicity has had contradictory results in other malignancies, such as hematological cancers [56,57]. Other functional polymorphisms in the same gene (such as 1298A/C) or in different genes of the folate pathway could also be analyzed in further studies.

The lack of Hardy–Weinberg equilibrium (HWE) in MTHFR 677 genotype distribution observed only in the OS group could be a confirmation of a true association between this polymorphism and the disease [58], although the small sample size (n = 55) cannot be ruled out as the reason for this lack of equilibrium. Genotyping errors, an important cause of deviation from HWE, were not detected by a second genotyping methodology used in this study. However, bias may have been introduced into the study by the different DNA sources (blood for the controls and paraffin-embedded tissue for the cases). Another study limitation was the absence of environmental factors, such as diet. It has been demonstrated that polymorphisms can interact with multiple factors to modify neoplasia risk and therefore environmental factor analysis should be included in future studies on MTHFR and OS.

Differences in tumor manifestation, the potential to undergo effective chemotherapy, and variations in the fundamental biology of tumors, are aspects to consider between pediatric and adult patients with osteosarcoma [7]. An important characteristic of the present study was that it included osteosarcoma patients between 8 and 67 years old (mean age of 18 years). This must be taken into account when comparing the present study with similar studies.

5. Conclusions

In conclusion, it can be stated that the MTHFR gene 677T/T genotype is negatively associated with OS in the population studied, occurring in a significantly lower proportion in patients with OS than in healthy subjects. This suggests that the folate mechanism is a factor that may have an influence on the malignant transformation of bone cells. Undoubtedly, further studies using large samples and carried out on different populations are necessary to evaluate the role of the MTHFR polymorphism in OS development.

Author Contributions

Conceptualization, I.G.E.-M. and I.D.-E.; Methodology, A.R.-M., J.O.-I. and R.O.-L.; Validation, M.L.M.-F.; Formal analysis, I.P.R.-S.; Investigation, C.A.S.-R. and A.Z.-P.; Data curation, K.S.-M.; Writing—original draft preparation, D.A.M.-G. and I.D.-E.; Writing—review and editing, D.A.M.-G., A.E.H.-R. and I.D.-E.; Supervision, A.R.-H. and I.G.-V.; Project administration, I.D.-E. All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Ethics Committee of University of Colima’s School of Medicine, Mexico, and authorized by the Department of Education of the Hospital de Especialidades N° 25 del IMSS NL, Mexico.

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Conflicts of Interest

The authors declare no conflicts of interest.

pediatrrep-16-00066-t001_Table 1 Table 1 Comparison of the MTHFR gene 677T/T genotype with other genotypes, between cases (patients with osteosarcoma) and controls.

Genotypes	Cases
n = 55	Controls
n = 180	OR (95%CI)	p *	
C/C	18	48	Reference		
T/T ‡	4	40	0.27 (0.06–0.91)	0.03	
C/T	33	92	Reference		
T/T ‡	4	40	0.28 (0.07–0.87)	0.02	
C/C-C/T	51	140	Reference		
T/T ‡	4	40	0.27 (0.07–0.82)	0.02	
C/C	18	48	Reference		
C/T ‡	33	92	0.96 (0.46–1.98)	0.89	
An association analysis was performed to obtain the crude odds ratios (OR) with their 95% confidence intervals (CI) and p values. The genotypes considered as exposure factor (‡), or as reference, are indicated. * Chi-square test with Yates correction.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
==== Refs
References

1. Bo Y. Zhu Y. Tao Y. Li X. Zhai D. Bu Y. Wan Z. Wang L. Wang Y. Yu Z. Association Between Folate and Health Outcomes: An Umbrella Review of Meta-Analyses Front. Public Health 2020 8 550753 10.3389/fpubh.2020.550753 33384976
2. Feigerlova E. Demarquet L. Guéant J.-L. One carbon metabolism and bone homeostasis and remodeling: A review of experimental research and population studies Biochimie 2016 126 115 123 10.1016/j.biochi.2016.04.009 27086080
3. Iqbal M.P. Ahmed M. Umer M. Mehboobali N. Qureshi A.A. Effect of methotrexate and folinic acid on skeletal growth in mice Acta Pædiatrica 2003 92 1438 1444 10.1111/j.1651-2227.2003.tb00829.x 14971796
4. Chou A.J. Geller D.S. Gorlick R. Therapy for osteosarcoma: Where do we go from here? Pediatr. Drugs 2008 10 315 327 10.2165/00148581-200810050-00005
5. Jones G. Early life nutrition and bone development in children Early Nutrition: Impact on Short- and Long-Term Health S.Karger AG Basel, Switzerland 2011 Volume 68 227 236 227–233; discussion 233–236
6. Cagnacci A. Bagni B. Zini A. Cannoletta M. Generali M. Volpe A. Relation of folates, vitamin B12 and homocysteine to vertebral bone mineral density change in postmenopausal women. A five-year longitudinal evaluation Bone 2008 42 314 320 10.1016/j.bone.2007.10.022 18289506
7. Kim C. Davis L.E. Albert C.M. Samuels B. Roberts J.L. Wagner M.J. Osteosarcoma in Pediatric and Adult Populations: Are Adults Just Big Kids? Cancers 2023 15 5044 10.3390/cancers15205044 37894411
8. Lemaire V. Tobin F.L. Greller L.D. Cho C.R. Suva L.J. Modeling the interactions between osteoblast and osteoclast activities in bone remodeling J. Theor. Biol. 2004 229 293 309 10.1016/j.jtbi.2004.03.023 15234198
9. Rautiainen S. Manson J.E. Lichtenstein A.H. Sesso H.D. Dietary supplements and disease prevention—A global overview Nat. Rev. Endocrinol. 2016 12 407 420 10.1038/nrendo.2016.54 27150288
10. Miller J.W. Borowsky A.D. Marple T.C. McGoldrick E.T. Dillard-Telm L. Young L.J.T. Green R. Folate, DNA methylation, and mouse models of breast tumorigenesis Nutr. Rev. 2008 66 (Suppl. S1) S59 S64 10.1111/j.1753-4887.2008.00070.x 18673493
11. Suormala T. Gamse G. Fowler B. 5,10-Methylenetetrahydrofolate reductase (MTHFR) assay in the forward direction: Residual activity in MTHFR deficiency Clin. Chem. 2002 48 835 843 10.1093/clinchem/48.6.835 12028998
12. Frosst P. Blom H.J. Milos R. Goyette P. Sheppard C.A. Matthews R.G. Boers G.J.H. Den Heijer M. Kluijtmans L.A.J. Van Den Heuve L.P. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase Nat. Genet. 1995 10 111 113 10.1038/ng0595-111 7647779
13. Cortese C. Motti C. MTHFR gene polymorphism, homocysteine and cardiovascular disease Public Health Nutr. 2001 4 493 497 10.1079/PHN2001159 11683544
14. Graziano F. Kawakami K. Ruzzo A. Watanabe G. Santini D. Pizzagalli F. Bisonni R. Mari D. Floriani I. Catalano V. Methylenetetrahydrofolate reductase 677C/T gene polymorphism, gastric cancer susceptibility and genomic DNA hypomethylation in an at-risk Italian population Int. J. Cancer 2006 118 628 632 10.1002/ijc.21397 16094648
15. Stevens V.L. McCullough M.L. Pavluck A.L. Talbot J.T. Feigelson H.S. Thun M.J. Calle E.E. Association of polymorphisms in one-carbon metabolism genes and postmenopausal breast cancer incidence Cancer Epidemiol. Biomark. Prev. 2007 16 1140 1147 10.1158/1055-9965.EPI-06-1037 17548676
16. Langevin S.M. Lin D. Matsuo K. Gao C.M. Takezaki T. Stolzenberg-Solomon R.Z. Vasavi M. Hasan Q. Taioli E. Review and pooled analysis of studies on MTHFR C677T polymorphism and esophageal cancer Toxicol. Lett. 2009 184 73 80 10.1016/j.toxlet.2008.09.003 18840514
17. Tang C. Yu S. Jiang H. Li W. Xu X. Cheng X. Peng K. Chen E. Cui Y. Liu T. A Meta-Analysis: Methylenetetrahydrofolate Reductase C677T Polymorphism in Gastric Cancer Patients Treated with 5-Fu Based Chemotherapy Predicts Serious Hematologic Toxicity but Not Prognosis J. Cancer 2018 9 1057 1066 10.7150/jca.23391 29581785
18. Miao X. Xing D. Tan W. Qi J. Lu W. Lin D. Susceptibility to gastric cardia adenocarcinoma and genetic polymorphisms in methylenetetrahydrofolate reductase in an at-risk Chinese population Cancer Epidemiol. Biomark. Prev. 2002 11 1454 1458
19. Matsuo K. Suzuki R. Hamajima N. Ogura M. Kagami Y. Taji H. Kondoh E. Maeda S. Asakura S. Kaba S. Association between polymorphisms of folate- and methionine-metabolizing enzymes and susceptibility to malignant lymphoma Blood 2001 97 3205 3209 10.1182/blood.V97.10.3205 11342450
20. Kaluzna E.M. Strauss E. Swiatek-Koscielna B. Zajac-Spychala O. Gowin E. Nowak J.S. Rembowska J. Januszkiewicz-Lewandowska D. The methylenetetrahydrofolate reductase 677T-1298C haplotype is a risk factor for acute lymphoblastic leukemia in children Medicine 2017 96 e9290 10.1097/MD.0000000000009290 29390492
21. Wiemels J.L. Smith R.N. Taylor G.M. Eden O.B. Alexander F.E. Greaves M.F. United Kingdom Childhood Cancer Study Investigators Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia Proc. Natl. Acad. Sci. USA 2001 98 4004 4009 10.1073/pnas.061408298 11274424
22. Ozger H. Kilicoglu O. Yilmaz H. Ergen H.A. Yaylim I. Zeybek U. Isbir T. Methylenetetrahydrofolate reductase C677T gene polymorphism in osteosarcoma and chondrosarcoma patients Folia Biol. 2008 54 53 57
23. Patiño-García A. Zalacaín M. Marrodán L. San-Julián M. Sierrasesúmaga L. Methotrexate in pediatric osteosarcoma: Response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression J. Pediatr. 2009 154 688 693 10.1016/j.jpeds.2008.11.030 19159907
24. Delgado-Enciso I. Martínez-Garza S.G. Rojas-Martínez A. Espinoza-Gómez F. Canseco-Avila L.M. Vidal-Gutiérrez O. Garza-Leal J.G. Barboza-Quintana O. Flores-Gutiérrez J.P. Barrera-Saldaña H.A. The effect of MTHFR polymorphisms, pregnancy and first intercourse on cervical cancer in a population from the Northeastern Mexico Rev. Investig. Clin. 2006 58 462 469 17408107
25. Miranda-Novales M.G. Villasís-Keever M.Á. El protocolo de investigación VIII. La ética de la investigación en seres humanos Rev. Alerg. México 2019 66 115 122 10.29262/ram.v66i1.594
26. Morgan K. Lam L. Kalsheker N. A rapid and efficient method for DNA extraction from paraffin wax embedded tissue for PCR amplification Clin. Mol. Pathol. 1996 49 M179 M180 10.1136/mp.49.3.M179 16696069
27. de Villarreal L.E.M. Delgado-Enciso I. Valdéz-Leal R. Ortíz-López R. Rojas-Martínez A. Limón-Benavides C. Sánchez-Peña M.A. Ancer-Rodríguez J. Barrera-Saldaña H.A. Villarreal-Pérez J.Z. Folate levels and N(5),N(10)-methylenetetrahydrofolate reductase genotype (MTHFR) in mothers of offspring with neural tube defects: A case-control study Arch. Med. Res. 2001 32 277 282 10.1016/S0188-4409(01)00292-2 11440783
28. Krajinovic M. Lamothe S. Labuda D. Lemieux-Blanchard E. Theoret Y. Moghrabi A. Sinnett D. Role of MTHFR genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia Blood 2004 103 252 257 10.1182/blood-2003-06-1794 12958073
29. Dean A.G. Arner T.G. Sunki G.G. Friedman R. Lantinga M. Sangam S. Zubieta J.C. Sullivan K.M. Brendel K.A. Gao Z. Epi InfoTM, a Database and Statistics Program for Public Health Professionals CDC Atlanta, GA, USA 2011
30. Santos F.A.B. Lemes R.B. Otto P.A. HW_TEST, a program for comprehensive HARDY-WEINBERG equilibrium testing Genet. Mol. Biol. 2020 43 e20190380 10.1590/1678-4685-gmb-2019-0380 32422648
31. Kon I.Y. Safronova A.I. Gmoshinskaya M.V. Shcheplyagina L.A. Korosteleva M.M. Toboleva M.A. Aleshina I.V. Kurkova V.I. Larionova Z.G. Bone mineral density in pregnant women from Moscow: Possible effects of pregnancy dynamics and nutrient intake Vopr. Pitan. 2014 83 58 65
32. Tobias J.H. Steer C.D. Emmett P.M. Tonkin R.J. Cooper C. Ness A.R. ALSPAC Study Team Bone mass in childhood is related to maternal diet in pregnancy Osteoporos. Int. 2005 16 1731 1741 10.1007/s00198-005-1912-6 15905998
33. Cagnacci A. Baldassari F. Rivolta G. Arangino S. Volpe A. Relation of homocysteine, folate, and vitamin B12 to bone mineral density of postmenopausal women Bone 2003 33 956 959 10.1016/j.bone.2003.07.001 14678855
34. Villa M.L. Marcus R. Ramírez Delay R. Kelsey J.L. Factors contributing to skeletal health of postmenopausal Mexican-American women J. Bone Miner. Res. 1995 10 1233 1242 10.1002/jbmr.5650100814 8585428
35. Golbahar J. Hamidi A. Aminzadeh M.A. Omrani G.R. Association of plasma folate, plasma total homocysteine, but not methylenetetrahydrofolate reductase C667T polymorphism, with bone mineral density in postmenopausal Iranian women: A cross-sectional study Bone 2004 35 760 765 10.1016/j.bone.2004.04.018 15336613
36. Dean L. Methylenetetrahydrofolate Reductase Deficiency Medical Genetics Summaries Pratt V. McLeod H. Dean L. Malheiro A. Rubinstein W. National Center for Biotechnology Information (US) Bethesda, MD, USA 2012
37. Macdonald H.M. McGuigan F.E. Fraser W.D. New S.A. Ralston S.H. Reid D.M. Methylenetetrahydrofolate reductase polymorphism interacts with riboflavin intake to influence bone mineral density Bone 2004 35 957 964 10.1016/j.bone.2004.05.018 15454103
38. Shiraki M. Urano T. Kuroda T. Saito M. Tanaka S. Miyao-Koshizuka M. Inoue S. The synergistic effect of bone mineral density and methylenetetrahydrofolate reductase (MTHFR) polymorphism (C677T) on fractures J. Bone Miner. Metab. 2008 26 595 602 10.1007/s00774-008-0878-9 18979159
39. Xie L. Guo W. Yang Y. Ji T. Xu J. More severe toxicity of genetic polymorphisms on MTHFR activity in osteosarcoma patients treated with high-dose methotrexate Oncotarget 2018 9 11465 11476 10.18632/oncotarget.23222 29545912
40. Lambrecht L. Sleurs C. Labarque V. Dhooge C. Laenen A. Sinnaeve F. Renard M. Uyttebroeck A. The role of the MTHFR C677T polymorphism in methotrexate-induced toxicity in pediatric osteosarcoma patients Pharmacogenomics 2017 18 787 795 10.2217/pgs-2017-0013 28592186
41. Karimi-Zarchi M. Moghimi M. Abbasi H. Hadadan A. Salimi E. Morovati-Sharifabad M. Akbarian-Bafghi M.J. Zare-Shehneh M. Mosavi-Jarrahi A. Neamatzadeh H. Association of MTHFR 677C>T Polymorphism with Susceptibility to Ovarian and Cervical Cancers: A Systematic Review and Meta-Analysis Asian Pac. J. Cancer Prev. 2019 20 2569 2577 10.31557/APJCP.2019.20.9.2569 31554347
42. Purnomo A.F. Daryanto B. Seputra K.P. Budaya T.N. Lutfiana N.C. Nurkolis F. Chung S. Suh J.Y. Park M.N. Seo B.K. Methylenetetrahydrofolate Reductase C677T (rs1801133) Polymorphism Is Associated with Bladder Cancer in Asian Population: Epigenetic Meta-Analysis as Precision Medicine Approach Cancers 2023 15 4402 10.3390/cancers15174402 37686678
43. Galván-Portillo M.V. Oñate-Ocaña L.F. Pérez-Pérez G.I. Chen J. Herrera-Goepfert R. Chihu-Amparan L. Flores-Luna L. Mohar-Betancourt A. López-Carrillo L. Dietary folate and vitamin B12 intake before diagnosis decreases gastric cancer mortality risk among susceptible MTHFR 677TT carriers Nutrition 2010 26 201 208 10.1016/j.nut.2009.05.006 19577428
44. Liu Y. Zhou L.S. Xu X.M. Deng L.Q. Xiao Q.K. Association of dietary intake of folate, vitamin B6 and B12 and MTHFR genotype with breast cancer risk Asian Pac. J. Cancer Prev. 2013 14 5189 5192 10.7314/APJCP.2013.14.9.5189 24175799
45. You J. Huang Y. Shen X. Chen Y. Ding X. Associations between MTHFR gene polymorphisms (C677T and A1298C) and genetic susceptibility to prostate cancer: A systematic review and meta-analysis Front. Genet. 2024 15 1343687 10.3389/fgene.2024.1343687 38343693
46. Lal H. Sharma B. Sambyal V. Guleria K. Singh N.R. Uppal M.S. Manjari M. Sudan M. Association of MTHFR 677C>T polymorphism with breast cancer risk: A case-control study and meta-analysis J. Cancer Res. Ther. 2022 18 1451 1460 36412394
47. Wang Y. Huo L. Yang C. He X. Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and gastric cancer susceptibility: An updated meta-analysis Biosci. Rep. 2023 43 BSR20222553 10.1042/BSR20222553 36896928
48. Li Y. Pei Y.X. Wang L.N. Liang C. Tang Y.L. Zhang X.L. Huang L.B. Luo X.Q. Ke Z.Y. MTHFR-C677T Gene Polymorphism and Susceptibility to Acute Lymphoblastic Leukemia in Children: A Meta-Analysis Crit. Rev. Eukaryot. Gene Expr. 2020 30 125 136 10.1615/CritRevEukaryotGeneExpr.2020033468 32558492
49. Moore L.E. Wiencke J.K. Bates M.N. Zheng S. Rey O.A. Smith A.H. Investigation of genetic polymorphisms and smoking in a bladder cancer case-control study in Argentina Cancer Lett. 2004 211 199 207 10.1016/j.canlet.2004.04.011 15219943
50. Xu W. Zhang H. Wang F. Wang H. Quantitative assessment of the association between MHTFR C677T (rs1801133, Ala222Val) polymorphism and susceptibility to bladder cancer Diagn. Pathol. 2013 8 95 10.1186/1746-1596-8-95 23773402
51. Sharp L. Little J. Polymorphisms in genes involved in folate metabolism and colorectal neoplasia: A HuGE review Am. J. Epidemiol. 2004 159 423 443 10.1093/aje/kwh066 14977639
52. Ulaner G.A. Vu T.H. Li T. Hu J.F. Yao X.M. Yang Y. Gorlick R. Meyers P. Healey J. Ladanyi M. Loss of imprinting of IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation changes of a CTCF-binding site Hum. Mol. Genet. 2003 12 535 549 10.1093/hmg/ddg034 12588801
53. Xu L. Wang L. Xue B. Wang S. MTHFR variant is associated with high-dose methotrexate-induced toxicity in the Chinese osteosarcoma patients J. Bone Oncol. 2018 13 143 147 10.1016/j.jbo.2018.10.002 30591868
54. Zhang W. Liu Z. Yang Z. Feng C. Zhou X. Tu C. Li Z. MTHFR Polymorphism Is Associated with Severe Methotrexate-Induced Toxicity in Osteosarcoma Treatment Front. Oncol. 2021 11 781386 10.3389/fonc.2021.781386 34976820
55. Liu B. Liu G. Liu B. Guo Y. Peng N. Li T. Correlation between gene polymorphism and adverse reactions of high-dose methotrexate in osteosarcoma patients: A systematic review and meta-analysis World J. Surg. Oncol. 2024 22 19 10.1186/s12957-023-03287-0 38212758
56. Lopez-Lopez E. Martin-Guerrero I. Ballesteros J. Garcia-Orad A. A systematic review and meta-analysis of MTHFR polymorphisms in methotrexate toxicity prediction in pediatric acute lymphoblastic leukemia Pharmacogenom. J. 2013 13 498 506 10.1038/tpj.2012.44 23089671
57. Guo Q. Sun J.L. Li R. Li X. Involvement of the ABCB1 C3435T Variant but Not the MTHFR C677T or MTHFR A1298C Variant in High-Dose Methotrexate-Induced Toxicity in Pediatric Acute Lymphoblastic Leukemia Patients in China Int. J. Gen. Med. 2024 17 1221 1231 10.2147/IJGM.S453394 38559593
58. Lee W.-C. Searching for disease-susceptibility loci by testing for Hardy-Weinberg disequilibrium in a gene bank of affected individuals Am. J. Epidemiol. 2003 158 397 400 10.1093/aje/kwg150 12936892
